Challenges in social communication and interaction are core symptoms in autism spectrum disorder (ASD) for which social skills group training (SSGT) is a commonly used intervention.
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental condition with a prevalence of 1-2%.
1,2 A multitude of alterations in social communication and interaction are among the core challenges in ASD. 3 The clinical presentation is heterogeneous, and the condition often co-occurs with other complications, such as attention-deficit hyperactivity disorder (ADHD), anxiety and depression, intellectual disability, and variety of somatic disorders. 4, 5 Reflecting the nature of the spectrum of clinical manifestations, the causes of ASD are diverse. Genetic factors, both common and rare play a significant part in the etiology of the disorder with complex interplay with each other and environmental factors. 6, 7 There is a scarcity of evidence-based interventions for ASD. 8 A commonly used intervention to ameliorate social communication difficulties and their negative impact on adaptive outcomes in the normative intellectual range of ASD is social skills group training (SSGT). SSGT is based on a combination of behavioral modification and socially instructive techniques applied in cohesive and safe peer group settings. The accumulated body of randomized controlled trials (RCTs) on SSGT suggest that the average effect is modest. [9] [10] [11] However, the overall heterogeneity of the outcome suggests that subgroup analyses might help identify moderators and mediators. The largest RCT on SSGT to date is the KONTAKT program 12 led by our center, found that the effect on social skills of a 12-week training was restricted to adolescents and females. 10 Further, a previous uncontrolled trial of SSGT KONTAKT found language capacities to be positively correlated with outcome, while ASD severity negatively impacted the outcome. 13 Another previous SSGT trial did not find the outcome to be associated with ADHD, level of social anxiety, Theory-of-Mind, or desire for social interaction. 14 However, the sample size was insufficient for informative subgroup analyses. with a molecular diagnostic yield up to 25%. [17] [18] [19] In addition to providing information about the genetic causes and recurrence risks for family members, CMA has been reported to result in individual medical intervention recommendations such as referral to specialists, surveillance protocols, and family investigations. 20, 21 An unanswered question of high relevance for clinical practice is whether CMA results can guide the selection and prioritization of interventions in ASD. To address this question, we performed analyzes of the potential moderating effect of CNVs on the outcome of a cohort following a 12-weeks training of SSGT KONTAKT. To increase the probability of clinically useful results, we focused on rare genic CNVs, including chromosomal aneuploidies, based on the current clinical recommendations of CMA evaluation in ASD.
Methods

Study Design
Data from the 12-week multicenter, randomized pragmatic clinical trial of the Swedish version of SSGT "KONTAKT" (hereafter referred to SSGT) 12 and genetic screening were used for this study. The initial trial tested the effectiveness of SSGT as a complement to standard care in 13 child and adolescent psychiatry outpatient units in Sweden. Outcome measures were collected at pre-, post-intervention (12-weeks) and follow-up (3-months after post-intervention). The protocol and results from the trial have been published previously. 10, 12 The study was approved by the ethical review board in Stockholm, Sweden (Dnr 2012/385-31/4) and the clinical authorities of the two involved counties. The trial was also registered online (NCT01854346). Written consent from the parents or legal guardians and verbal assent from the youth were collected. The trial and the collection of saliva samples were done between August 2012 and October 2015.
Participants
The trial included 296 youths aged 8 to 17 years with ASD. Eligibility criteria and recruitment of participants are described in detail elsewhere. 10 In short, participants had a clinical consensus diagnosis of autism, atypical autism, Asperger syndrome, or pervasive developmental disorder not otherwise specified based on ICD-10 criteria. 22 The diagnosis was corroborated by ASD cutoffs (modules 3 or 4) on the Autism Diagnostic Observation Schedule (ADOS). 23 Additionally, the ADOS total scores were used to estimate the autism severity at baseline. All participants had full-scale IQs > 70, according to the Wechsler Intelligence Scale for Children (third or fourth edition) 24 and at least one common comorbid psychiatric ICD-10 diagnosis of ADHD, anxiety disorder, or mood disorder. Participants providing saliva samples and primary outcome data for at least one-time point (post-intervention or 3-months follow-up) were included in the planned subgroup analyzes of CNV carriers (N=209; 106 from the SSGT group, 103 from the 'standard care' group). We also used the baseline measures from the participants without saliva samples (n= 87) to analyze if any differences were observed between the included and excluded participants.
Outcome Measures
The primary outcome measure was the change in total raw scores on the parent reported Social
Responsiveness Scale (SRS). 25 Higher values on the SRS scale indicate greater severity of autistic symptoms. Secondary outcome measures used in the RCT were parent ratings on the Adaptive Behavior Assessment System II (ABAS-II) 26 , the trainer-rated Developmental Disabilities modification of the Children's Global Assessment Scale (DD-CGAS) 27 and Ohio
State University (OSU) Global Severity Scale for Autism (OSU Autism-CGI-S). 28 Genotyping and CNV Calling
The participants collected saliva samples using the Oragene•DNA OG-500 tubes (DNA Genotek, Inc., Ottawa, Ontario, Canada) at home using a recommended procedure. Thereafter, For the statistical analyses, we considered only variants that were called by both algorithms and spanned at least 25 kb and 25 consecutive probes. 29 If large CNVs were found to affect the sex chromosomes, the calls were manually inspected using ChAS software (Affymetrix) to verify the call and check for possible chromosomal aneuploidies. As we sought to limit analyses to CNVs that would be included in clinical CMA reports, we removed variants that were present with more than 0.1% frequency in the general population using the Ontario Population Genomics Platform (OPGP) data as reference. 29 In OPGP, 873 samples were genotyped using the same Affymetrix platform. Additionally, we removed variants that overlapped more than five variants that are reported in the Database of Genomic Variants (DGV). 30 The CNVs were mapped using GRCh37/hg19 coordinates. Thereafter, CNVs that overlapped at least one coding exon based on the gene annotation from RefSeq were included in the final CNV set. We performed experimental validation of 15 selected CNVs using quantitative polymerase chain reaction (qPCR).
Statistical Analyses
CNV status was coded binary with "0" for non-carriers and "1" for carriers. The rare genic CNVs were categorized based on their size into three groups: 25-100 kb (small), 101-500 kb (middlesize), and >500kb including chromosome aneuploidies (large). The participants were grouped according to the largest CNV present. The effects of all rare genic CNVs, and the three CNV size groups, on the outcome were tested separately using mixed linear models (MLM). Based on our primary hypothesis that rare CNVs would affect the outcome of SSGT, we first tested the twoway interaction of CNV carrier*time (post-intervention and 3-months follow-up) in the active SSGT participant group. Thereafter, we examined if significant results would remain after including the 'standard care' group in a three-way interaction CNV carrier*time*intervention group (SSGT vs. 'standard care'). Our primary MLM model included the fixed effects of age group (children or adolescents) and sex, as these had shown to influence intervention outcome in the RCT study. 10 To account for the putative differences between participating centers and individuals, these were included as random effects in the models. The least-square (LS) means, and 95% confidence interval (CI) were calculated. The secondary model included IQ as a covariate based on previous studies suggesting an association of CNVs with IQ and educational attainment in the general population. 31, 32 The effect sizes were calculated by dividing the group difference in the change of least-squares means from pre-intervention to post-intervention/followup by the pooled standard deviation at pre-intervention. Additionally, we tested for differences in clinical group characteristics at baseline (SRS, IQ, ADOS total score) between the participants included and excluded in this study within the SSGT and standard care group as well as between rare genic CNV carriers and non-carriers using two-sided student's t-test and χ 2 test. The analyses were conducted using R version 3.4.2.
Results
Demographics and clinical characteristics of the participants included in this study are presented in Table 1 , stratified by intervention group. After genotyping and CNV quality control two samples (one from SSGT and one from standard care group) were removed. Therefore, 105 children were included in the active SSGT group and 102 in the standard care group. Eightyseven participants (29.3%) from the RCT were excluded due to unavailable saliva sample for the genetic analysis. IQ was significantly lower in the SSGT participants without a saliva sample (eTable 1). No other differences in the baseline measures were seen between the included and excluded participants (eTable 1). The participants without saliva samples had a higher frequency of missing primary outcome data in both SSGT and standard care groups (eTable 2). (OMIM*300128), and KDM5B (OMIM*605393).
The sex and age group (children or adolescents) adjusted results for the primary outcome are reported in Table 2 , and the estimated LS-means are shown in Figure 1 . No differences were found for the carriers of rare genic CNVs at post-intervention or follow-up in comparison with non-carriers. We then stratified the data by size of the CNVs, the carriers of large genic CNVs (>500 kb), including chromosomal aneuploidies, had inferior outcome at post-intervention (β = 15.35, 95% CI 2.9-27.8, P = .017) and at follow-up (β = 14.19, 95% CI 1.7-26.7, P = .028) compared with participants without large genic CNVs (Table 2, Figure 1 ). Changes between preand post-intervention/follow-up for the carriers and non-carries are shown in eFigure 2. We observed medium effect sizes for both time points (-0.47 at post and -0.43 at follow-up) showing the negative impact of large CNVs on the outcome in comparison with participants without large
CNVs. An opposite effect, however, was observed for carriers of middle-size CNVs at follow-up (β =-8.69, 95% CI -16.8 --0.6, P = .038) with an effect size of 0.28. In the three-way interaction model, when including the standard care group to assure the specificity of effect for SSGT, the significant effect for large genic CNV carriers in SSGT group remained at post-intervention (β = 21.90, 95% CI 1.5 -42.3, P = .036) with a similar trend at follow-up (β =18.82, 95% CI -1.6 -39.3, P = .072) ( Table 2 , Figure 1 The recent molecular evidence in ASD hopefully can be used to design effective medical interventions targeting ASD core symptoms. 33 However, there is still a long road ahead until such interventions can be introduced on the market and implemented in clinical practice. Therefore, it is crucial to investigate how genetic information can help to enhance treatment decisions using current and widely applied behavioral ASD programs. Studies on potential genetic moderators of both pharmacological (pharmacogenomics) and psychological treatments (therapygenetics) in psychiatry has started to emerge in recent years. 34, 35 For instance, a recent study showed that individuals with bipolar disorder and high genetic load as measured by polygenic scores for schizophrenia had an inadequate response to lithium treatment. 36 Additionally, a study investigating the association of CNVs with response to antidepressant medication in major depressive disorder showed no general effect, but the authors noted less response for carriers of CNVs in specific loci, including NRXN1. 37 For therapygenetics, recent studies have mostly used common genetic variants either in selected candidate genes 38 or a hypothesis-free genome-wide approach 39 with no or limited evidence of genetic moderators of treatment response. We used a more refined approach, by investigating rare genic CNVs that are associated with a large risk for ASD as well as other neurodevelopmental and psychiatric disorders. 40, 41 To the best of our knowledge, our study is the first to investigate therapygenetics in ASD.
Our data also show that CMA is useful in testing for genetic alterations in autistic individuals in the average and high intellectual range. We identified rates of clinically significant CNVs (7.2%) similar to what has previously been reported in samples including individuals with ASD in the intellectual disability range. [17] [18] [19] Interestingly, our results seem to corroborate previous studies showing that individuals with ASD and genomic or monogenic syndromes form a subgroup characterized by lower cognitive abilities and milder ASD symptomatology, especially for social communication alterations. 42, 43 Similarly, an earlier study using machine learning classification showed that individuals with specified genetic disorders in ASD have a specific signature of social impairment. 44 Therefore, it is crucial to better understand the intervention needs of those with specified molecular alterations. For instance, it should not be ruled out that this group could benefit from longer periods of training. We recently reported that a long version of KONTAKT (24-weeks) resulted in larger effects in general than we have found for the 12-weeks version used here. 45 Unfortunately, that trial was not sufficiently powered for subgroup analyzes.
Limitations of our study should be noted. First, while this study was based on the largest RCT in ASD research to date, the sample was still limited to investigate effects of single loci.
Thus, our results reflect various molecular causes. Second, data on either saliva or the primary outcome were missing for 87 (29%) of the participants enrolled in the trial, and these participants from the active SSGT group had significantly lower IQ. Third, the secondary outcome measures provided a somewhat inconsistent picture, underscoring the preliminary nature of the results.
Fourth, the showed subgroup differences should be interpreted with caution. These limitations must be addressed in future studies before specific clinical recommendations can be made based on CNVs. From a clinical and practical perspective, we would also like to stress that there are many social, economical, legal and ethical issues to be addressed as the genetic and genomic testing in ASD is rapidly increasing. These include, but are not limited to, realistic cost-benefit analyses, genetic data protection, clinical guideline development, and the avoidance of discrimination of genetic and ethnic minorities. 46, 47, 6 Conclusions This is the first study to show that individuals with ASD and large rare genic CNVs are less likely than non-carriers to benefit from SSGT. He is an author of the German and Swedish KONTAKT manuals and receives royalties.
Dr. Berggren has received personal fees from Kompetento, Expo Medica, and Pysslingen group.
Other authors do not report biomedical financial interests or potential conflicts of interest. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
